London, May 7, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.
This course provides a guide to the commonly used methods and tools in structural bioinformatics to analyse and interpret experimentally determined and AI-predicted macromolecular structure data.
Structural biology, determining the three-dimensional shapes of biomacromolecules and their complexes, can tell us a lot about how these molecules function and the roles they play within a cell. Data derived from structure determination experiments and Artificial Intelligence (AI)-assisted structure prediction enables life-science researchers to address a wide variety of questions.
Learn about the tools, processes, and analysis approaches used in the field of genome-resolved metagenomics.
This course will cover the use of publicly available resources to manage, share, analyse, and interpret metagenomics data, focussing primarily on assembly-based approaches.
The delivered content will involve participants learning via live lectures and presentations, followed by live Q&As with the trainers. Practical experience will be developed in group activities and in computational exercises run using containerised tools on our training infrastructure.
Data presented at Digestive Disease Week in San Diego
Cambridge, UK – 6 May 2025: Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.
Read May eNews here 👉 https://shorturl.at/4OR54
Featuring:
The Role
We are seeking a talented and creative Bioinformatician with a passion for using computational advances to improve every step of the antibody drug discovery process.
Spark Therapeutics veteran brings over 25 years’ of leadership experience to drive translation of company’s bicistronic gene therapies into products.
– Camgenium and Cardiac Tech have developed an innovative solution to adverse events caused by current temporary pacing methods used in intensive care wards –
– Pace-Protect will be the first medical device using a Soft Silicon™ mesh network to be deployed in a clinical environment –